A recent investigation from KFF Health News about payments to members of an FDA panel evaluating an Abbott Laboratories cardiac device is raising eyebrows.

CMS must ensure transparency, clarity and predictability by providing detailed guidance on comparator drug selection and the evaluation of evidence, according to a group of D.C.-based health policy researchers.

This recall is due to reports of “increased resistance” when using the devices. There have been 194 customer complaints about the issue so far. 

Medicaid’s $50 billion in improper payments was the highest total for a single program—but it was also the most improved government program, cutting about $30 billion from its 2022 improper payments total. 

An expansion in access to mifepristone for telehealth patients is at risk before the Supreme Court. What does this mean for the FDA approvals process?

The FDA has issued a Class I recall for Vyaire Medical respiratory support devices, saying use of older, defective devices could result in injury or death.

More than 5,000 U.S. physicians joined forces to launch the new group. They say they are focused on limiting private equity's involvement and influence in healthcare. 

“Given the unprecedented magnitude of this cyberattack, and in the best interest of patients and health care providers, OCR is initiating an investigation into this incident,” states a “Dear Colleague” letter from OCR director Melanie Fontes Rainer.